Core Viewpoint - The company, Vanguard Pharmaceuticals (00399.HK), has entered into a placement agreement to issue up to 145 million shares at a price of HKD 0.415 per share, which represents a discount of approximately 9.78% from the closing price of HKD 0.460 on the date of the agreement [1] Group 1 - The placement is expected to involve at least six independent third-party subscribers [1] - The estimated net proceeds from the placement, after deducting related expenses of approximately HKD 1.35 million, are expected to be around HKD 58.825 million [1] - The company intends to use the net proceeds entirely for funding the development of its blockchain technology business [1]

Core Viewpoint - The company,领航医药生物科技, has announced a placement agreement to issue up to 145 million shares at a price of HKD 0.415 per share, representing a discount of approximately 9.78% from the closing price on August 21, 2025 [1] Group 1: Placement Details - The placement is expected to involve at least six independent third-party subscribers [1] - The maximum number of shares to be placed represents about 6.34% of the enlarged issued share capital [1] - If all shares are fully placed, the total proceeds from the placement will be approximately HKD 60.175 million [1] Group 2: Financial Implications - After deducting related expenses estimated at HKD 1.35 million, the net proceeds from the placement are expected to be around HKD 58.825 million [1] - The company intends to use the net proceeds entirely for funding the development of its blockchain technology business [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司任何證券之邀請或要約。 INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 領航醫藥及生物科技有限公 司 （於開曼群島註冊成立並於百慕達存續之有限公 司） （股份代 號：399） 根據一般授權配售新股份 配售代理 根據一般授權配售新股份 於二零二五年八月二十一日（聯交所交易時段結束後），本公司與配售代理訂 立配售協議，據此，配售代理已有條件同意擔任本公司代理，以竭誠促使目 前預期不少於六名承配人（彼等及其最終實益擁有人應為獨立第三方）按每股 配售股份0.415港元的配售價認購最多145,000,000股配售股份。 假設本公司已發行股本於本公告日期至完成配售事項日期期間不會有變，最 多145,000,000股配售股份佔(i)於本公告日期本公司現有已發行股本約6.77%； 及(ii)經配發及發行所有配售股份擴大的本公司已發行股本約 ...

Core Viewpoint - The stock of Vanguard Medical Biotechnology (00399) experienced a significant decline of 7.69%, trading at HKD 0.42 per share with a transaction volume of HKD 5.9847 million as of 10:26 AM on August 21 [1] Company Overview - Vanguard Medical Biotechnology focuses on the research and development of oral insulin products, as well as the trade of beauty instruments and products [1] - The company is committed to acquiring commercially viable pharmaceutical products and was formerly known as United Gene Technology Group [1] - It is currently listed on the main board of the Hong Kong Stock Exchange under stock code 399 [1] Financial Performance - As of the 2024 annual report, Vanguard Medical Biotechnology reported total revenue of HKD 1.9296 million and a net loss of HKD 319 million [2]

Core Viewpoint - The cryptocurrency concept stocks in Hong Kong experienced a collective rise, indicating a positive market sentiment towards this sector [1]. Group 1: Stock Performance - Leading stocks included: - Navigating Medical Biotechnology rose by 7.69%, with a latest price of 0.490 and a market capitalization of 1.039 billion [2]. - New Fire Technology Holdings increased by 7.28%, priced at 7.220, with a total market value of 42.3 billion [2]. - Guotai Junan International saw a rise of 6.46%, trading at 5.440, with a market cap of 51.827 billion [2]. - OK Blockchain rose by 5.56%, priced at 0.570, with a market capitalization of 3.061 billion [2]. - Xiong'an Technology increased by 5.31%, with a price of 0.119 and a market cap of 0.0142 billion [2]. - Blueport Interactive rose by 3.95%, priced at 0.790, with a market capitalization of 0.0292 billion [2]. - Mistrategy increased by 3.08%, trading at 4.350, with a market cap of 1.601 billion [2]. - OSL Group rose by 2.97%, priced at 17.350, with a market capitalization of 12.801 billion [2]. - Huajian Medical increased by 2.70%, trading at 8.380, with a market cap of 135.74 billion [2]. - Jinyong Investment rose by 2.25%, priced at 9.980, with a market cap of 25.6 billion [2]. - Huaxing Capital Holdings increased by 2.16%, trading at 7.580, with a market cap of 4.346 billion [2].

（股份代 號：399） 延長最後截止日期 茲提述本公司日期為二零二五年七月十五日及二零二五年七月十六日的公告（「該 等公告」），內容有關張彪兵及陳靜按每股認購股份0.3124港元的認購價分別認 購本公司60,000,000股股份及30,000,000股股份。除文義另有規定外，本公告所 用詞彙與該等公告所界定者具有相同涵義。 認購協議A INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 領航醫藥及生物科技有限公 司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立並於百慕達存續之有限公 司） 領航醫藥及生物科技有限公司 由於需要額外時間達成認購協議A所載的先決條件，故本公司已於二零二五年 八月五日與認購人A訂立延長函件，以將最後截止日期由二零二五年八月五日 延長至二零二五年八月二十六日或認購人A與本公司可能書面協定的其他日期 及時間。 除上文所述者外，補充協議A（經補充協議A修訂及補充）的所有其他條 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 公司名稱: 領航醫藥生物科技有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00399 | 說明 | 領航醫藥生物科技 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 50,000,000,000 | HKD | | 0.01 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 50,000,000,000 | HKD | | 0.01 | HKD | | 500,000,000 | 本月底法定/註冊股本 ...

Core Viewpoint - The stock of Pioneer Pharma Biotechnology (00399) experienced a decline of 6.35% on August 1, trading at HKD 0.59 per share with a transaction volume of HKD 1.093 million [1]. Group 1: Company Overview - Pioneer Pharma Biotechnology focuses on the research and development of pharmaceutical products and the trade of beauty instruments and products, particularly oral insulin products [1]. - The company is actively seeking pharmaceutical products with commercial development potential to expand its research and development scope [1]. - Pioneer Pharma is listed on the main board of the Hong Kong Stock Exchange under stock code 399 [1]. Group 2: Financial Performance - As of the 2024 annual report, Pioneer Pharma Biotechnology reported total revenue of HKD 1.9296 million and a net loss of HKD 319 million [2].

Group 1 - The company proposes to change its English name from "Innovative Pharmaceutical Biotech Limited" to "Starcoin Group Limited" [1] - The Chinese name will be updated to "星太链集团有限公司" to replace the existing name "领航医药及生物科技有限公司" [1]

智通财经APP讯，领航医药生物科技(00399)发布公告，根据行使于2013年10月25日发行的可换股债券的 转换权而于2025年7月31日发行换股股份1.485亿股。 ...